Transparency notification Vanguard Health Care Fund
Brussels (Belgium), 18 October 2019 – 20:00 (CEST) – regulated information
1. Summary of the notification
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Vanguard Health Care Fund (having its registered office at c/o The Vanguard Group, Inc. 400 Devon Park Drive, Wayne PA, 19087 USA), dated 15 October 2019.
Vanguard Health Care Fund, has notified that, following a disposal of voting rights, its holding of UCB shares with voting rights has decreased and has crossed downwards the 5% threshold to 0.00% on 1 October 2019.
On 1 October 2019, Vanguard Health Care Fund, owned 0 UCB shares with voting rights (versus 9 741 353 shares in its previous notification), representing 0.00% of the total number of shares issued by the company (194 505 658) (versus 5.01% in its previous notification).
2. Content of the notification
- Reason for the notification: Acquisition or disposal of voting securities or voting rights.
- Notification by: A person that notifies alone.
- Person subject to the notification requirement:
- Date on which the threshold is crossed: 1 October 2019.
- Threshold crossed (in %): 5%
- Denominator: 194 505 658.
- Notified details:
- Chain of controlled undertakings through which the holding is effectively held:
The Vanguard Health Care Fund has thousands of shareholders and no individual shareholder controls the fund.
- Additional information:
Externally managed Vanguard funds have granted proxy voting responsibilities to their portfolio managers effective 01 October 2019.
3. Further information
This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.
Investor Relations, UCB
T +32.2.559.94.14 email@example.com
Investor Relations, UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Stay up-to-date on the latest news and information from UCB